Comparative Efficacy of Flunarizine and Propanolol in Pediatric Migraine
ConditionMigraine
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age8-15
SponsorMuhammad Aamir Latif
About this trial
Flunarizine and propranolol have demonstrated efficacy in reducing migraine frequency across age groups, though evidence in pediatric populations remains limited and inconsistent. Therefore, the current study has been planned to evaluate and compare the effectiveness of flunarizine and propranolol in reducing migraine frequency in children aged 8-15 using the Pediatric Migraine Disability Assessment Scale (PedMIDAS) score.
Eligibility criteria
Qualifiers
Children of any gender
Aged 8-15 years
Diagnosed with migraine (with/without aura) per International Classification of Headache Disorders, 3rd Edition (ICHD-3) criteria
A history of ≥4 migraine attacks/month for the preceding 3 months
Disqualifiers
Children with secondary headache disorders (e.g., due to infections, trauma, structural brain lesions)
Known hypersensitivity or contraindications to flunarizine or propranolol
Presence of cardiovascular disorders (e.g., bradycardia, heart block, hypotension, asthma)
Non-compliance or inability to attend regular follow-ups
Trial design
Treatments tested in this trial
- Flunarizine
- Propranolol
Treatment groups
44 Participants
are divided into 2 treatment groupsSponsors and collaborators
Muhammad Aamir Latif
Lead sponsor
RESnTEC, Institute of Research
Sponsor institution
Source ClinicalTrials.gov